All Episodes

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

Fibrosis, IPF and the search for better therapies

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

What makes life science angel investment work?

Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions

The next era of diabetes management

Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win

Funding the Future of European Biotech

J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer

Bonus: Q1 2026 Job Market Update

Automation, Collaboration and the Future of Advanced Therapies

Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma

The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

Beyond Buzzwords in Longevity Investing

Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More

Inside the Race to Build the Next Generation of AI Drug Discovery Platforms

Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter

From Two Trials to One, Sponsors Face a Higher Standard

Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data

Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead

From Grants to Family Offices: Building a Unified Financing Strategy in Biotech

UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More

ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs

Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval

Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer

Redefining Obesity Treatment Beyond GLP-1 Limits

Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

As FDA Moves Away From Animal Testing, AI and Organoids Can Shine

Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment

Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News

Programmable RNA 2.0: Beyond the First mRNA Revolution

Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs

Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides

Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More

From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM

JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return

Bonus: Q4 2025 Job Market Update

Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy

From Nuclear Winter to Renewal: Biotech Investing for 2026

Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus

Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum

Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets

Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment

Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs

New Approach Methodologies: Redefining Animal Testing Alternatives

Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs

Billions More in M&A, Another Bidding War and More FDA Drama

How Biotech Funding is Changing Executive Search and Hiring Processes

Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers

Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience

Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks

Innovation, Resilience, and the Future of Global Manufacturing

Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More

How Supply Chain Turbulence is Reshaping Biotech Strategy

Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn

Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma

Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing

Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC

Bonus: Q3 2025 Job Market Update

Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa

Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems

M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s

FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More

What Do AI and Hammers Have in Common?

China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More

Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More

The 'Research Safety Net' Saving Scientists from Funding Crisis

CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More

Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change

Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations

Why AI Won't Save the 90% of Clinical Trials That Still Fail

MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum

The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know

Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues

From Chat Bots to World Order: The Race for the 21st Century's Operating System

FDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More

We Don't Own Patient Data–We're Just Babysitting It

Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings

Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions

Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines

AI Is Taking Over Drug Safety Monitoring–But There's One Thing It Can't Replace

FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease

Bonus Episode: Q2 2025 Job Market Update

The mRNA Revolution You Haven't Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

Understanding the FDA's AI Guidance in Pharmacovigilance

FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap

Navigating Funding Freezes and AI Frontiers

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

RFK Axes CDC Vaccine Advisors ; Metsera’s Weight Loss Win; FDA Supports CGT

AI's Role in Decoding the FDA's New Regulatory Communications

M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama

COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN

How Target Product Profiles Guide the Industry Through Uncertain Times

Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan

Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter

Eroding Immunity: Vaccine Hesitancy and Cynicism

Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review

Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More

Economic Challenges, Strategic Investments: Reshaping the Women's Health Landscape

Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race

Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed

Bonus: Q1 2025 Job Market Update

Breaking Down Barriers: The Nuanced Approach to Women's Representation in Medical Research

Tariff-Triggered Recession Fears, Fallout From HHS Cuts, Knockoff GLP-1s and More

FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More

Balancing Protection and Inclusion: The Evolution of Women in Clinical Trials

Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More

Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio

A Conversation With Mark McKenna, CEO of Mirador

“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health

COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More

Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More

A Conversation With Kevin Marks, CEO of Delphia

Money Meets Medicine: A Disruptor's Guide to Life Sciences Investment

Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More

Examining Gene Therapies, Bispecific Antibodies and Other Novel Modalities

Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom

A Conversation With Dannielle Appelhans, CEO of COUR

Navigating Patient Journeys with Tom Whitehead

New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs

RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market

The Patient's Perspective with Tom Whitehead

RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More

Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM

Bonus: Q4 2024 Job Market Update

A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)

NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch

Trials and Capital: Women’s Health and APAC's Healthcare Revolution

Analysis vs Beliefs, CEO Challenges, GLP-1 Investments

Biopharma’s Manufacturing Push and Other 2024 Trends

Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More

Previous Investment Patterns Set to Repeat in 2025

Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More

BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More

51%: The Untapped Market

RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More

AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More

Investing in AI: Benefits, Regulatory Challenges

Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More

Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More

Steady But Slow: Future Outlook for Investment

Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More

Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More

How AI Could Ease Tension in Clinical Trials

BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More

BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day

AI Return on Investment: Just Because We Can, Should We?

Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval

Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024

AI Promises: Funding Data Literacy and Reality First

BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement

Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases

Future-Proofing: Inclusive and Protective Patient Strategies

A Tough Ending, New Beginnings and China-U.S. Biopharma Relations

New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity

Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations

Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More

Pharma Campaign Contributions, Vaccine Hiccups and Lykos’ Moment of Truth

The Political Shape of the Future Clinical Trial Space

2 Earnings Bonanza, M&A Accelerates and Alzheimer’s Data

Layoffs Persist, GLP-1s Launch for Weight Loss in China

Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?

Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure

Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists

FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues

DE&I: Understanding That We Don’t Understand at Molecular Level

Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights

BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap

Challenging Research Models to Improve Health Equity

BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More

BioSpace at #DIA2024: Convergence and Collaboration

Donanemab’s Promise, BIO Wrap and Mass Layoffs

BioSpace x DIA: Robust Integrated Regulatory Strategies

The ABCs of Biopharma This Week: ASCO, BIO and Cancer

BioSpace x DIA: Advanced Therapy Product Regulatory Confusion

AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO

BioSpace x DIA: Navigating the Emergence of CGT Combination Products

Bayer’s New Strategy, Novo Vs. Lilly and Psychedelics

Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap

Women's Health: Where Politics and Science Meet

ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird

BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy

The IRA, BMS’ Big Cuts, First WHIM Approval

Where Do We Go From Here? The Future of Women's Health

Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player

Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages

It's a Design Problem: Women and Clinical Trials

Alphabet Soup: AACR and ACC Dominate Headlines This Week

Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo

Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?

Bayer’s sweeping executive cuts, Wegovy’s expanding reach

Money talk: Salary trends and raises

Historic approval for MASH, CAR-Ts in the spotlight

The unintended consequences of small molecules

The skinny on weight loss, donanemab and the State of the Union

The ABCs of ADCs: Why antibody-drug conjugates are so hot right now

The gap is where the pain is: Drug pricing and patient costs

Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars

Iovance wins with Amtagvi and the ADC train chugs on

Eyes on the prize: Novo buys Catalent

Balancing act: Patient access and innovation

Keep calm and CAR-T on?

What can biopharma expect from the job market?

Grab an umbrella, it's raining ⁠IPOs⁠!

Optimistic, but for how long? Our big takeaways from #JPM2024

On the ground at #JPM2024 - Day 3 highlights

On the ground at #JPM2024 - Day 2 highlights

On the ground at #JPM2024 - Day 1 highlights

Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics

The top life sciences startups to watch this year

What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital

Every move you make: Biopharma industry under heavy scrutiny

What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital

Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny

Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA

Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA

GLP-1 and ADC rollercoasters pick up speed

Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior

Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety

Deals, Dupixent and GLP-1 drug shortages

First ever CRISPR gene therapy approval: What happens next?

Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure

Zepbound vs Wegovy: A two horse race

Q3 earnings recap: Winners, losers & surprises